## SAFETY DATA SHEET

**Antibodies Reagent IVD**

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1 Product identifier

**Product name**: Antibodies Reagent IVD

**Part no.**:
- 8920001, 8920002, 8920003, 8920004, 8920007, 8920008, 8920009, 8920011, 8920012, 8920013, 8920014, 8920015, 8920016, 8920017, 8920018, 8920022,
- 8920023, 8920028, 8920029, 8920036, 8920038, 8920039, 8920041, 8920043, 8920045, 8920048, 8920049, 8920050, 8920053, 8920054, 8920060, 8920064,
- 8920070, 8920084, 8920085, 8920086, 8920100, 8920108, 8920109, 8920114, 8920119, 8920120, 8920123, 8920130, 8920132, 8920140, 8920144, 8920158,
- 8920197, 8920200, 8920216, 8920230, 8920248, 8920249, 8920250, 8920251, 8920255, 8920261, 8920262, 8920263, 8920264, 8920265, 8920266, 8920267,
- 8920268, 8920269, 8920270, 8920271, 8920272, 8920273, 8920274, 8920276, 8920277, 8920278, 8920279, 8920280, 8920282, 8920331, 8920359, 8920103,
- 8921014, 8921015, 8921016, 8921017, 8921018, 8921019, 8921020, 8921021, 8921022, 8921023, 8921024, 8921025, 8921029, 8921030, 8921031, 8921032,
- 8921033, 8921034, 8921035, 8921036, 8921037, 8921042, 8921043, 8921044, 8921045, 8929995, 8929996, 8929997, 8929998, 8929999, 8930001, 8930002,
- 8930003, 8930004, 8930007, 8930008, 8930009, 8930011, 8930012, 8930013, 8930014, 8930015, 8930016, 8930017, 8930018, 8930022, 8930023, 8930028,
- 8930029, 8930036, 8930038, 8930039, 8930041, 8930043, 8930045, 8930048, 8930049, 8930050, 8930053, 8930054, 8930060, 8930064, 8930084, 8930085,
- 8930086, 8930108, 8930109, 8930114, 8930119, 8930120, 8930123, 8930130, 8930132, 8930144, 8930158, 8930200, 8930216, 8930230, 8930248, 8930249,
- 8930250, 8930261, 8930262, 8930263, 8930264, 8930265, 8930266, 8930267, 8930268, 8930269, 8930270, 8930271, 8930272, 8930273, 8930274, 8930276,
- 8930277, 8930278, 8930279, 8930280, 8930282, 8930331, 8930359, 8931013, 8931014, 8931015, 8931016, 8931017, 8931018, 8931019, 8931020, 8931021,
- 8931022, 8931023, 8931024, 8931025, 8931029, 8931030, 8931031, 8931032, 8931033, 8931034, 8931035, 8931036, 8931037, 8931042, 8931043, 8931044,
- 8931045, 8939995, 8939996, 8939997, 8939998, 8939999, 8940012

### 1.2 Relevant identified uses of the substance or mixture and uses advised against

**Material uses**:

- For In Vitro Diagnostic Use
- 8920001 FITC Mouse anti-human CD3
- 8920002 PE Mouse anti-human CD8
- 8920003 APC Mouse anti-human CD4
- 8920004 PerCP Mouse anti-human CD45
- 8920007 APC Mouse anti-human CD19
- 8920008 CD3/CD8/CD45/CD4 antibody kit
- 8920009 CD3/CD16+CD56/CD45/CD19 antibody kit
- 8920011 FITC Mouse anti-human CD4
- 8920012 CD4/CD8/CD3 antibody kit
- 8920013 PerCP-Cyanine 5.5 Mouse anti-human CD3
- 8920014 FITC Mouse anti-human CD45
- 8920015 PE-Cy7 Mouse anti-human CD19
- 8920016 FITC Mouse anti-human CD19
- 8920017 PE Mouse anti-human CD19
- 8920018 PE Mouse anti-human CD1a
- 8920022 FITC Mouse anti-human CD2
- 8920023 PE Mouse anti-human CD2
- 8920028 PE Mouse anti-human CD4
- 8920029 PE-Cy7 Mouse anti-human CD4
- 8920036 PE Mouse anti-human CD7
- 8920038 FITC Mouse anti-human CD8
- 8920039 APC Mouse anti-human CD8
- 8920041 PE-Cy7 Mouse anti-human CD8
- 8920043 FITC Mouse anti-human CD10
Antibodies Reagent IVD

SECTION 1: Identification of the substance/mixture and of the company/undertaking

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>8920045</td>
<td>APC Mouse anti-human CD10</td>
</tr>
<tr>
<td>8920048</td>
<td>PE Mouse anti-human CD11b</td>
</tr>
<tr>
<td>8920049</td>
<td>APC Mouse anti-human CD11b</td>
</tr>
<tr>
<td>8920050</td>
<td>PE Mouse anti-human CD11c</td>
</tr>
<tr>
<td>8920053</td>
<td>PE Mouse anti-human CD13</td>
</tr>
<tr>
<td>8920054</td>
<td>PE-Cy7 Mouse anti-human CD13</td>
</tr>
<tr>
<td>8920060</td>
<td>FITC Mouse anti-human CD15</td>
</tr>
<tr>
<td>8920064</td>
<td>FITC Mouse anti-human CD16</td>
</tr>
<tr>
<td>8920070</td>
<td>FITC Mouse anti-human CD20</td>
</tr>
<tr>
<td>8920084</td>
<td>PE Mouse anti-human CD25</td>
</tr>
<tr>
<td>8920085</td>
<td>APC Mouse anti-human CD25</td>
</tr>
<tr>
<td>8920086</td>
<td>PE-Cy7 Mouse anti-human CD25</td>
</tr>
<tr>
<td>8920100</td>
<td>PE Mouse anti-human CD34</td>
</tr>
<tr>
<td>8920108</td>
<td>FITC Mouse anti-human CD38</td>
</tr>
<tr>
<td>8920109</td>
<td>PE Mouse anti-human CD38</td>
</tr>
<tr>
<td>8920114</td>
<td>APC Mouse anti-human CD56</td>
</tr>
<tr>
<td>8920119</td>
<td>PE Mouse anti-human CD64</td>
</tr>
<tr>
<td>8920120</td>
<td>FITC Mouse anti-human CD71</td>
</tr>
<tr>
<td>8920123</td>
<td>PE Mouse anti-human CD79a</td>
</tr>
<tr>
<td>8920130</td>
<td>PE Mouse anti-human CD117</td>
</tr>
<tr>
<td>8920132</td>
<td>PE-Cy7 Mouse anti-human CD117</td>
</tr>
<tr>
<td>8920140</td>
<td>APC Mouse anti-human CD138</td>
</tr>
<tr>
<td>8920144</td>
<td>APC Mouse anti-human HLA-DR</td>
</tr>
<tr>
<td>8920158</td>
<td>FITC Mouse anti-human ZAP-70</td>
</tr>
<tr>
<td>8920197</td>
<td>FITC HLA-B27 / PerCP CD3 antibody Kit</td>
</tr>
<tr>
<td>8920200</td>
<td>PE Mouse anti-human CD5</td>
</tr>
<tr>
<td>8920216</td>
<td>APC-Cyanine 7 Mouse anti-human HLA-DR</td>
</tr>
<tr>
<td>8920230</td>
<td>APC Mouse anti-human CD5</td>
</tr>
<tr>
<td>8920248</td>
<td>APC Mouse anti-human CD61</td>
</tr>
<tr>
<td>8920249</td>
<td>FITC Mouse anti-human CD15</td>
</tr>
<tr>
<td>8920250</td>
<td>CD3/CD16+56/CD45/CD19 antibody kit</td>
</tr>
<tr>
<td>8920251</td>
<td>CD3/CD16+56/CD45/CD4/CD19/CD8 kit</td>
</tr>
<tr>
<td>8920255</td>
<td>PE Mouse anti-human CD22</td>
</tr>
<tr>
<td>8920261</td>
<td>FITC Mouse anti-human MPO</td>
</tr>
<tr>
<td>8920262</td>
<td>APC Mouse anti-human CD79a</td>
</tr>
<tr>
<td>8920263</td>
<td>PE-Cy7 Mouse anti-human CD3</td>
</tr>
<tr>
<td>8920264</td>
<td>APC-Cyanine 7 Mouse anti-human CD45</td>
</tr>
<tr>
<td>8920265</td>
<td>APC-Cyanine 7 Mouse anti-human CD8</td>
</tr>
<tr>
<td>8920266</td>
<td>PE-Cy7 Mouse anti-human CD23</td>
</tr>
<tr>
<td>8920267</td>
<td>APC-Cy7 Mouse anti-human CD36</td>
</tr>
<tr>
<td>8920268</td>
<td>APC-Cyanine 7 Mouse anti-human CD38</td>
</tr>
<tr>
<td>8920269</td>
<td>PE-Cy7 Mouse anti-human CD45RA</td>
</tr>
<tr>
<td>8920270</td>
<td>PE Mouse anti-human CD45RO</td>
</tr>
<tr>
<td>8920271</td>
<td>APC Mouse anti-human CD45RO</td>
</tr>
<tr>
<td>8920272</td>
<td>FITC Mouse anti-human CD62P</td>
</tr>
<tr>
<td>8920273</td>
<td>PE Mouse anti-human CD69</td>
</tr>
<tr>
<td>8920274</td>
<td>PE Mouse anti-human CD127</td>
</tr>
<tr>
<td>8920276</td>
<td>FITC Mouse anti-human CD14</td>
</tr>
<tr>
<td>8920277</td>
<td>APC Mouse anti-human CD14</td>
</tr>
<tr>
<td>8920278</td>
<td>APC Mouse anti-human CD56</td>
</tr>
<tr>
<td>8920279</td>
<td>APC-Cyanine 7 Mouse anti-human CD56</td>
</tr>
<tr>
<td>8920280</td>
<td>PE-Cy7 Mouse anti-human CD33</td>
</tr>
<tr>
<td>8920282</td>
<td>APC Mouse anti-human CD33</td>
</tr>
<tr>
<td>8920331</td>
<td>PE-Cy7 Mouse anti-human CD11c</td>
</tr>
<tr>
<td>8920959</td>
<td>FITC Mouse anti-human CD45RA</td>
</tr>
<tr>
<td>8921013</td>
<td>PerCP-Cyanine 5.5 Mouse anit-human CD45</td>
</tr>
<tr>
<td>8921014</td>
<td>FITC Mouse anti-human CD45</td>
</tr>
<tr>
<td>8921015</td>
<td>PerCP-Cyanine 5.5 Mouse anti-CD3</td>
</tr>
<tr>
<td>8921016</td>
<td>FITC Mouse anti-human CD3</td>
</tr>
<tr>
<td>8921017</td>
<td>PerCP Mouse anti-human CD45</td>
</tr>
<tr>
<td>8921018</td>
<td>FITC Mouse anti-human CD4</td>
</tr>
</tbody>
</table>
Antibodies Reagent IVD

SECTION 1: Identification of the substance/mixture and of the company/undertaking

8921019 APC Mouse anti-human CD4
8921020 PE-Cy7 Mouse anti-human CD4
8921021 PE Mouse anti-human CD4
8921022 PE Mouse anti-human CD8
8921023 FITC Mouse anti-human CD8
8921024 PE-Cy7 Mouse anti-human CD8
8921025 APC Mouse anti-human CD8
8921029 APC-Cyanine7 Mouse anti-human CD2
8921030 PerCP-Cyanine5.5 Mouse anti-human CD33
8921031 APC-Fire™750 Mouse anti-human CD117
8921032 APC-Fire™750 Mouse anti-human HLA-DR
8921033 APC-Fire™750 Mouse anti-human CD3
8921034 PerCP-Cyanine5.5 Mouse anti-human CD4
8921035 PE-Cyanine7 Mouse anti-human CD7
8921036 APC-Fire™750 Mouse anti-human CD10
8921037 APC Mouse anti-human CD13
8921042 PE Mouse anti-human CD23
8921043 APC Mouse anti-human CD36
8921044 PE-Cy7 Mouse anti-human CD56
8921045 PE-Dazzle™594 Mouse anti-human CD56
8929995 PE Mouse anti-human CD59
8929996 FITC Mouse anti-human CD14
8929997 PE Mouse anti-human CD64
8929998 PerCP Mouse anti-human CD45
8929999 APC Mouse anti-human HLA-DR
8930001 FITC Mouse anti-human CD3
8930002 PE Mouse anti-human CD8
8930003 APC Mouse anti-human CD4
8930004 PerCP Mouse anti-human CD45
8930007 APC Mouse anti-human CD19
8930008 CD3/C8/CD45/CD4 antibody kit
8930009 CD3/CD16+CD56/CD45/CD19 antibody kit
8930011 FITC Mouse anti-human CD4
8930012 CD4/CD8/CD3 antibody kit
8930013 PerCP-Cyanine 5.5 Mouse anti-CD3
8930014 FITC Mouse anti-human CD45
8930015 PE-Cy7 Mouse anti-human CD19
8930016 FITC Mouse anti-human CD19
8930017 PE Mouse anti-human CD19
8930018 PE Mouse anti-human CD1a
8930022 FITC Mouse anti-human CD2
8930023 PE Mouse anti-human CD2
8930028 PE Mouse anti-human CD4
8930029 PE-Cy7 Mouse anti-human CD4
8930036 PE Mouse anti-human CD7
8930038 FITC Mouse anti-human CD8
8930039 APC Mouse anti-human CD8
8930041 PE-Cy7 Mouse anti-human CD8
8930043 FITC Mouse anti-human CD10
8930045 APC Mouse anti-human CD10
8930048 PE Mouse anti-human CD11b
8930049 APC Mouse anti-human CD11b
8930050 PE Mouse anti-human CD11c
8930053 PE Mouse anti-human CD13
8930054 PE-Cy7 Mouse anti-human CD13
8930060 FITC Mouse anti-human CD15
8930064 FITC Mouse anti-human CD16
8930084 PE Mouse anti-human CD25
8930085 APC Mouse anti-human CD25
8930086 PE-Cy7 Mouse anti-human CD25
8930108 FITC Mouse anti-human CD38

Date of issue/Date of revision : 27/04/2021  Date of previous issue : 21/12/2020  Version : 2
### SECTION 1: Identification of the substance/mixture and of the company/undertaking

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>8930109</td>
<td>PE Mouse anti-human CD38</td>
</tr>
<tr>
<td>8930114</td>
<td>APC Mouse anti-human CD56</td>
</tr>
<tr>
<td>8930119</td>
<td>PE Mouse anti-human CD64</td>
</tr>
<tr>
<td>8930120</td>
<td>FITC Mouse anti-human CD71</td>
</tr>
<tr>
<td>8930123</td>
<td>PE Mouse anti-human CD79a</td>
</tr>
<tr>
<td>8930130</td>
<td>PE Mouse anti-human CD117</td>
</tr>
<tr>
<td>8930132</td>
<td>PE-Cy7 Mouse anti-human CD117</td>
</tr>
<tr>
<td>8930144</td>
<td>APC Mouse anti-human HLA-DR</td>
</tr>
<tr>
<td>8930158</td>
<td>FITC Mouse anti-human ZAP-70</td>
</tr>
<tr>
<td>8930200</td>
<td>PE Mouse anti-human CD5</td>
</tr>
<tr>
<td>8930216</td>
<td>APC-Cyanine 7 Mouse anti-human HLA-DR</td>
</tr>
<tr>
<td>8930230</td>
<td>APC Mouse anti-human CD5</td>
</tr>
<tr>
<td>8930248</td>
<td>APC Mouse anti-human CD61</td>
</tr>
<tr>
<td>8930249</td>
<td>FITC Mouse anti-human CD15</td>
</tr>
<tr>
<td>8930250</td>
<td>CD3/CD16+CD56/CD45/CD19 antibody kit</td>
</tr>
<tr>
<td>8930261</td>
<td>FITC Mouse anti-human MPO</td>
</tr>
<tr>
<td>8930262</td>
<td>APC Mouse anti-human CD79a</td>
</tr>
<tr>
<td>8930263</td>
<td>PE-Cy7 Mouse anti-human CD3</td>
</tr>
<tr>
<td>8930264</td>
<td>APC-Cyanine 7 Mouse anti-human CD45</td>
</tr>
<tr>
<td>8930265</td>
<td>APC-Cyanine 7 Mouse anti-human CD8</td>
</tr>
<tr>
<td>8930266</td>
<td>PE-Cy7 Mouse anti-human CD23</td>
</tr>
<tr>
<td>8930267</td>
<td>APC-Cy7 Mouse anti-human CD36</td>
</tr>
<tr>
<td>8930268</td>
<td>APC-Cyanine 7 Mouse anti-human CD38</td>
</tr>
<tr>
<td>8930269</td>
<td>PE-Cy7 Mouse anti-human CD45RA</td>
</tr>
<tr>
<td>8930270</td>
<td>PE Mouse anti-human CD45RO</td>
</tr>
<tr>
<td>8930271</td>
<td>APC Mouse anti-human CD45RO</td>
</tr>
<tr>
<td>8930272</td>
<td>FITC Mouse anti-human CD62P</td>
</tr>
<tr>
<td>8930273</td>
<td>PE Mouse anti-human CD69</td>
</tr>
<tr>
<td>8930274</td>
<td>PE Mouse anti-human CD127</td>
</tr>
<tr>
<td>8930276</td>
<td>FITC Mouse anti-human CD14</td>
</tr>
<tr>
<td>8930277</td>
<td>APC Mouse anti-human CD14</td>
</tr>
<tr>
<td>8930278</td>
<td>APC Mouse anti-human CD56</td>
</tr>
<tr>
<td>8930279</td>
<td>APC-Cyanine 7 Mouse anti-human CD56</td>
</tr>
<tr>
<td>8930280</td>
<td>PE-Cy7 Mouse anti-human CD33</td>
</tr>
<tr>
<td>8930282</td>
<td>APC Mouse anti-human CD33</td>
</tr>
<tr>
<td>8930331</td>
<td>PE-Cy7 Mouse anti-human CD11c</td>
</tr>
<tr>
<td>8930959</td>
<td>FITC Mouse anti-human CD45RA</td>
</tr>
<tr>
<td>8931013</td>
<td>PerCP-Cyanine 5.5 Mouse anti-human CD45</td>
</tr>
<tr>
<td>8931014</td>
<td>FITC Mouse anti-human CD45</td>
</tr>
<tr>
<td>8931015</td>
<td>PerCP-Cyanine 5.5 Mouse anti-human-CD3</td>
</tr>
<tr>
<td>8931016</td>
<td>FITC Mouse anti-human CD3</td>
</tr>
<tr>
<td>8931017</td>
<td>PerCP Mouse anti-human CD45</td>
</tr>
<tr>
<td>8931018</td>
<td>FITC Mouse anti-human CD4</td>
</tr>
<tr>
<td>8931019</td>
<td>APC Mouse anti-human CD4</td>
</tr>
<tr>
<td>8931020</td>
<td>PE-Cy7 Mouse anti-human CD4</td>
</tr>
<tr>
<td>8931021</td>
<td>PE Mouse anti-human CD8</td>
</tr>
<tr>
<td>8931022</td>
<td>FITC Mouse anti-human CD8</td>
</tr>
<tr>
<td>8931023</td>
<td>PE-Cy7 Mouse anti-human CD8</td>
</tr>
<tr>
<td>8931024</td>
<td>APC Mouse anti-human CD8</td>
</tr>
<tr>
<td>8931025</td>
<td>APC-Cyanine7 Mouse anti-human CD2</td>
</tr>
<tr>
<td>8931030</td>
<td>PerCP-Cyanine5.5 Mouse anti-human CD33</td>
</tr>
<tr>
<td>8931031</td>
<td>APC-Fire™750 Mouse anti-human CD117</td>
</tr>
<tr>
<td>8931032</td>
<td>APC-Fire™750 Mouse anti-human HLA-DR</td>
</tr>
<tr>
<td>8931033</td>
<td>APC-Fire™750 Mouse anti-human CD3</td>
</tr>
<tr>
<td>8931034</td>
<td>PerCP-Cyanine5.5 Mouse anti-human CD4</td>
</tr>
<tr>
<td>8931035</td>
<td>PE-Cyanine7 Mouse anti-human CD7</td>
</tr>
<tr>
<td>8931036</td>
<td>APC-Fire™750 Mouse anti-human CD10</td>
</tr>
<tr>
<td>8931037</td>
<td>APC Mouse anti-human CD13</td>
</tr>
<tr>
<td>8931042</td>
<td>PE Mouse anti-human CD23</td>
</tr>
<tr>
<td>8931043</td>
<td>APC Mouse anti-human CD36</td>
</tr>
</tbody>
</table>
SECTION 1: Identification of the substance/mixture and of the company/undertaking

8931044  PE-Cy7 Mouse anti-human CD56
8931045  PE-Dazzle™594 Mouse anti-human CD56
8939995  PE Mouse anti-human CD59
8939996  FITC Mouse anti-human CD14
8939997  PE Mouse anti-human CD64
8939998  PerCP Mouse anti-human CD45
8939999  APC Mouse anti-human HLA-DR
8940012  CD4/CD8/CD3 antibody kit

1.3 Details of the supplier of the safety data sheet
Agilent Technologies Manufacturing GmbH & Co. KG
Hewlett-Packard-Str. 8
76337 Waldbronn
Germany
0800 603 1000

e-mail address of person responsible for this SDS
pdl-msds_author@agilent.com

1.4 Emergency telephone number
Emergency telephone number (with hours of operation)
CHEMTREC®: +(44)-870-8200418

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture
Product definition: Mixture
Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]
Not classified.

See Section 16 for the full text of the H statements declared above.
See Section 11 for more detailed information on health effects and symptoms.

2.2 Label elements

Signal word: No signal word.
Hazard statements: No known significant effects or critical hazards.

Precautionary statements
Prevention: Not applicable.
Response: Not applicable.
Storage: Not applicable.
Disposal: Not applicable.

Supplemental label elements
Annex XVII - Restrictions on the manufacture, placing on the market, and use of certain dangerous substances, mixtures and articles: Not applicable.

Special packaging requirements
SECTION 2: Hazards identification

2.3 Other hazards

Product meets the criteria for PBT or vPvB according to Regulation (EC) No. 1907/2006, Annex XIII: This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

Other hazards which do not result in classification: None known.

SECTION 3: Composition/information on ingredients

3.2 Mixtures: Mixture

There are no ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section.

Occupational exposure limits, if available, are listed in Section 8.

SECTION 4: First aid measures

4.1 Description of first aid measures

Eye contact: Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Get medical attention if irritation occurs.

Inhalation: Remove victim to fresh air and keep at rest in a position comfortable for breathing. Get medical attention if symptoms occur.

Skin contact: Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Get medical attention if symptoms occur.

Ingestion: Wash out mouth with water. Remove victim to fresh air and keep at rest in a position comfortable for breathing. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Do not induce vomiting unless directed to do so by medical personnel. Get medical attention if symptoms occur.

Protection of first-aiders: No action shall be taken involving any personal risk or without suitable training.

4.2 Most important symptoms and effects, both acute and delayed

Potential acute health effects

Eye contact: No known significant effects or critical hazards.

Inhalation: No known significant effects or critical hazards.

Skin contact: No known significant effects or critical hazards.

Ingestion: No known significant effects or critical hazards.

Over-exposure signs/symptoms

Eye contact: No specific data.

Inhalation: No specific data.

Skin contact: No specific data.

Ingestion: No specific data.

4.3 Indication of any immediate medical attention and special treatment needed

Notes to physician: Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.

Specific treatments: No specific treatment.
SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media: Use an extinguishing agent suitable for the surrounding fire.

Unsuitable extinguishing media: None known.

5.2 Special hazards arising from the substance or mixture

Hazards from the substance or mixture: In a fire or if heated, a pressure increase will occur and the container may burst.

Hazardous combustion products: No specific data.

5.3 Advice for firefighters

Special precautions for fire-fighters: Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.

Special protective equipment for fire-fighters: Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

For non-emergency personnel: No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spill material. Put on appropriate personal protective equipment.

For emergency responders: If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".

6.2 Environmental precautions: Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).

6.3 Methods and material for containment and cleaning up

Methods for cleaning up: Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

6.4 Reference to other sections: See Section 1 for emergency contact information. See Section 8 for information on appropriate personal protective equipment. See Section 13 for additional waste treatment information.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Protective measures: Put on appropriate personal protective equipment (see Section 8).

Advice on general occupational hygiene: Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.
SECTION 7: Handling and storage

7.2 Conditions for safe storage, including any incompatibilities

**Storage**
Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

7.3 Specific end use(s)

**Recommendations**
Industrial applications, Professional applications.

**Industrial sector specific solutions**
Not available.

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

**Occupational exposure limits**
No exposure limit value known.

**Recommended monitoring procedures**
If this product contains ingredients with exposure limits, personal, workplace atmosphere or biological monitoring may be required to determine the effectiveness of the ventilation or other control measures and/or the necessity to use respiratory protective equipment. Reference should be made to monitoring standards, such as the following: European Standard EN 689 (Workplace atmospheres - Guidance for the assessment of exposure by inhalation to chemical agents for comparison with limit values and measurement strategy) European Standard EN 14042 (Workplace atmospheres - Guide for the application and use of procedures for the assessment of exposure to chemical and biological agents) European Standard EN 482 (Workplace atmospheres - General requirements for the performance of procedures for the measurement of chemical agents) Reference to national guidance documents for methods for the determination of hazardous substances will also be required.

**DNELs/DMELs**
No DNELs/DMELs available.

**PNECs**
No PNECs available

8.2 Exposure controls

**Appropriate engineering controls**
Good general ventilation should be sufficient to control worker exposure to airborne contaminants.

**Individual protection measures**

**Hygiene measures**
Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

**Eye/face protection**
Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses with side-shields.

**Skin protection**
**SECTION 8: Exposure controls/personal protection**

**Hand protection**
- Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary.

**Body protection**
- Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

**Other skin protection**
- Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

**Respiratory protection**
- Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

**Environmental exposure controls**
- Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

**SECTION 9: Physical and chemical properties**

**9.1 Information on basic physical and chemical properties**

**Appearance**
- Physical state: Liquid.
- Colour: Not available.
- Odour: Not available.
- Odour threshold: Not available.
- pH: Not available.
- Melting point/freezing point: 0°C
- Initial boiling point and boiling range: 100°C
- Flash point: Not available.
- Evaporation rate: Not available.
- Flammability (solid, gas): Not applicable.
- Upper/lower flammability or explosive limits: Not available.
- Vapour pressure: Not available.
- Vapour density: Not available.
- Relative density: Not available.
- Solubility(ies): Soluble in the following materials: cold water and hot water.
- Partition coefficient: n-octanol/water: Not available.
- Auto-ignition temperature: Not available.
- Decomposition temperature: Not available.
- Viscosity: Not available.
- Explosive properties: Not available.
- Oxidising properties: Not available.

**9.2 Other information**
- No additional information.
SECTION 10: Stability and reactivity

10.1 Reactivity
: No specific test data related to reactivity available for this product or its ingredients.

10.2 Chemical stability
: The product is stable.

10.3 Possibility of hazardous reactions
: Under normal conditions of storage and use, hazardous reactions will not occur.

10.4 Conditions to avoid
: No specific data.

10.5 Incompatible materials
: May react or be incompatible with oxidising materials.

10.6 Hazardous decomposition products
: Under normal conditions of storage and use, hazardous decomposition products should not be produced.

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Acute toxicity
Not available.

Acute toxicity estimates
N/A

Irritation/Corrosion
Conclusion/Summary
: Not available.

Sensitiser
Conclusion/Summary
: Not available.

Mutagenicity
Conclusion/Summary
: Not available.

Carcinogenicity
Conclusion/Summary
: Not available.

Reproductive toxicity
Conclusion/Summary
: Not available.

Teratogenicity
Conclusion/Summary
: Not available.

Aspiration hazard
Not available.

Information on likely routes of exposure
: Not available.

Potential acute health effects

Inhalation
: No known significant effects or critical hazards.

Ingestion
: No known significant effects or critical hazards.

Skin contact
: No known significant effects or critical hazards.

Eye contact
: No known significant effects or critical hazards.

Symptoms related to the physical, chemical and toxicological characteristics

Inhalation
: No specific data.

Ingestion
: No specific data.

Skin contact
: No specific data.

Eye contact
: No specific data.

Delayed and immediate effects as well as chronic effects from short and long-term exposure

Date of issue/Date of revision
: 27/04/2021

Date of previous issue
: 21/12/2020

Version
: 2
SECTION 11: Toxicological information

Short term exposure
- Potential immediate effects: Not available.
- Potential delayed effects: Not available.

Long term exposure
- Potential immediate effects: Not available.
- Potential delayed effects: Not available.

Potential chronic health effects
- General: No known significant effects or critical hazards.
- Carcinogenicity: No known significant effects or critical hazards.
- Mutagenicity: No known significant effects or critical hazards.
- Reproductive toxicity: No known significant effects or critical hazards.

SECTION 12: Ecological information

12.1 Toxicity
Conclusion/Summary: Not available.

12.2 Persistence and degradability
Not available.

12.3 Bioaccumulative potential
Not available.

12.4 Mobility in soil
- Soil/water partition coefficient ($K_{OC}$): Not available.
- Mobility: Not available.

12.5 Results of PBT and vPvB assessment
This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

12.6 Other adverse effects: No known significant effects or critical hazards.

SECTION 13: Disposal considerations

13.1 Waste treatment methods
Product
Methods of disposal: The generation of waste should be avoided or minimised wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.

Hazardous waste: Within the present knowledge of the supplier, this product is not regarded as hazardous waste, as defined by EU Directive 2008/98/EC.
SECTION 13: Disposal considerations

Methods of disposal: The generation of waste should be avoided or minimised wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.

Special precautions: This material and its container must be disposed of in a safe way. Empty containers or liners may retain some product residues. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.

SECTION 14: Transport information

<table>
<thead>
<tr>
<th>14.1 UN number</th>
<th>ADR/RID</th>
<th>IMDG</th>
<th>IATA</th>
</tr>
</thead>
</table>

| 14.2 UN proper shipping name | - | - | - |
| 14.3 Transport hazard class(es) | - | - | - |
| 14.4 Packing group | - | - | - |
| 14.5 Environmental hazards | No. | No. | No. |

Additional information

14.6 Special precautions for user: Transport within user’s premises: always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

14.7 Transport in bulk according to IMO instruments: Not available.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

EU Regulation (EC) No. 1907/2006 (REACH)
Annex XIV - List of substances subject to authorisation
Annex XIV
None of the components are listed.
Substances of very high concern
None of the components are listed.
Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles
Label: Not applicable.

Other EU regulations
Ozone depleting substances (1005/2009/EU)
Not listed.
Prior Informed Consent (PIC) (649/2012/EU)
Not listed.
SECTION 15: Regulatory information

Seveso Directive
This product is not controlled under the Seveso Directive.

International regulations

Chemical Weapon Convention List Schedules I, II & III Chemicals
Not listed.

Montreal Protocol
Not listed.

Stockholm Convention on Persistent Organic Pollutants
Not listed.

Rotterdam Convention on Prior Informed Consent (PIC)
Not listed.

UNECE Aarhus Protocol on POPs and Heavy Metals
Not listed.

Inventory list
Australia : Not determined.
Canada : Not determined.
China : All components are listed or exempted.
Europe : All components are listed or exempted.
Japan : Japan inventory (ENCS): Not determined.
         Japan inventory (ISHL): Not determined.
New Zealand : Not determined.
Philippines : Not determined.
Republic of Korea : Not determined.
Taiwan : All components are listed or exempted.
Thailand : Not determined.
Turkey : Not determined.
United States : All components are active or exempted.
Viet Nam : Not determined.

15.2 Chemical safety assessment : This product contains substances for which Chemical Safety Assessments might still be required.

SECTION 16: Other information

Indicates information that has changed from previously issued version.

Abbreviations and acronyms:

ATE = Acute Toxicity Estimate
CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No. 1272/2008]
DMEL = Derived Minimal Effect Level
DNEL = Derived No Effect Level
EUH statement = CLP-specific Hazard statement
N/A = Not available
PBT = Persistent, Bioaccumulative and Toxic
PNEC = Predicted No Effect Concentration
RRN = REACH Registration Number
vPvB = Very Persistent and Very Bioaccumulative

Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

<table>
<thead>
<tr>
<th>Classification</th>
<th>Justification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not classified.</td>
<td></td>
</tr>
</tbody>
</table>

Full text of abbreviated H statements

Date of issue/Date of revision : 27/04/2021 Date of previous issue : 21/12/2020 Version : 2
SECTION 16: Other information

Not applicable.

Full text of classifications [CLP/GHS]
Not applicable.

Date of issue/Date of revision: 27/04/2021
Date of previous issue: 21/12/2020
Version: 2

Notice to reader

Disclaimer: The information contained in this document is based on Agilent’s state of knowledge at the time of preparation. No warranty as to its accurateness, completeness or suitability for a particular purpose is expressed or implied.